Orphazyme investor following muscle wasting disappointment: "Now everything has to run smoothly in 2021"

The rest of 2021 has to run perfectly for Orphazyme, according to portfolio manager, following the pharmaceutical firm's recent and disappointing study with main candidate arimoclomol for the muscle wasting disease IBM.

Photo: Orphazyme/PR

Following disappointing results for Orphazyme's main candidate arimoclomol against muscle wasting disease inclusion body myositis (IBM), which decreased the share price over 30 percent within a single trading day, the firm has two chances left which must be successful in order to set the company right again.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs